Cancer Research Matters – Side effects and sub-types

Cancer Research Matters provokes conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.

The first series focusses on the 20^th anniversary of CRUK – we’ll be winding back the clock on some of the great discoveries and breakthroughs made in the past two decades and asking some leading names where they think we’ll be in another 20 years.

This episode features Professor Richard Gilbertson. Richard is a paediatric oncology clinician scientist and is the Director of the Cancer Research UK Cambridge Centre. He has dedicated his career to understanding childhood brain tumours and is perhaps known best for his work identifying different types of medulloblastoma and ependymoma – two of the most common kinds of childhood brain tumour.

He talks about the challenges and successes of the childhood cancer research community, how he sees the future of the field and some of the incredible breakthroughs his lab has made on childhood brain cancers.

If you’d rather listen on the Acast site – click here

Further reading

WNT signalling and brain cancer
https://link.springer.com/article/10.1007/s00401-012-0958-8

https://www.sciencedirect.com/science/article/pii/S1535610816300551

Read about CRUK’s data strategy
https://news.cancerresearchuk.org/2022/07/07/joining-the-dots-how-our-new-research-data-strategy-will-unlock-the-power-of-big-data/

Data strategy
https://www.cancerresearchuk.org/sites/default/files/cancer_research_uk_-_research_data_strategy.pdf